USA Health, ADPH, HHS Partner to Expand Access to Covid-19 Therapy

USA Health, in partnership with the Alabama Department of Public Health (ADPH) and the U.S. Department of Health and Human Services (HHS), recently announced it has expanded access to COVID-19 monoclonal antibody (mAb) therapies and will begin administering treatment at the Mobile Civic Center. For people who are at high risk for developing severe COVID-19 illness and have tested positive for COVID-19 or have been exposed to someone who has tested positive, this mAb treatment has been shown to help prevent progression of the disease that might otherwise require hospitalization. USA Health will expand access to the mAb infusion for eligible patients with a new 10-chair unit in the Civic Center, enabling it to treat up to 70 patients per day. To confirm eligibility for the treatment and book an appointment, patients should contact 1-833-873-2826 or visit website.

Read More

The Haven To Participate In ASPCA Adoption Promotion

The Haven To Participate In ASPCA Adoption Promotion

Mobile Area Special Olympics To Benefit From Tidal Wave Charity Day

Mobile Area Special Olympics To Benefit From Tidal Wave Charity Day

Fort Morgan Trail Addition Now Open

Fort Morgan Trail Addition Now Open

AHSAA Regional Cheer Competition To Be Held September 30

AHSAA Regional Cheer Competition To Be Held September 30

Mack’s Wheelhouse Launches Product Line

Mack’s Wheelhouse Launches Product Line

Great Day Latte Receives Beer/Wine License Approval

Great Day Latte Receives Beer/Wine License Approval

Oktoberfest Coming To Fairhope Brewing

Oktoberfest Coming To Fairhope Brewing

Tickets Available Now For USA Commercial Real Estate Program Fall Forum

Tickets Available Now For USA Commercial Real Estate Program Fall Forum

Downtown Mobile Alliance Annual Luncheon Set For September 25

Downtown Mobile Alliance Annual Luncheon Set For September 25

Subscribe to our weekly newsletter

Sign up here for free to get Bay Business News email newsletter every Friday.

By subscribing, you agree to our User Agreement and Privacy Policy & Cookie Statement.

Something went wrong. Please check your entries and try again.